A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
NCT06821061 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2650
Last updated 2026-01-26
Summary
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together.
This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Conditions
- Influenza
- COVID-19 (Coronavirus Disease 2019)
Interventions
- BIOLOGICAL
-
Investigational Influenza Vaccine
Investigational Influenza Vaccine
- BIOLOGICAL
-
Investigational COVID-19 Vaccine
Investigational COVID-19 Vaccine
- COMBINATION_PRODUCT
-
Investigational Influenza and COVID-19 Combination Vaccine
Investigational Combined Influenza and COVID-19 Vaccine
- BIOLOGICAL
-
Licensed Influenza Vaccine 1
Licensed Influenza Vaccine 1
- BIOLOGICAL
-
Licensed Influenza Vaccine 2
Licensed Influenza Vaccine 2
- BIOLOGICAL
-
Licensed Influenza Vaccine 3
Licensed Influenza Vaccine 3
- BIOLOGICAL
-
Licensed COVID-19 Vaccine
Pfizer-BioNTech COVID-19 Vaccine
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-02-10
- Primary Completion
- 2025-12-17
- Completion
- 2025-12-17
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
NCT06680375 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
NCT06291857 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
NCT05827926 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
NCT06097273 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza
NCT05052697 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
NCT05160636 ·Status: ACTIVE_NOT_RECRUITING
-
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
NCT05375838 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
NCT06279871 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
NCT05091307 ·Status: COMPLETED ·Phase: PHASE3
-
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
NCT06436703 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older
NCT00848848 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
NCT06020118 ·Status: COMPLETED ·Phase: PHASE4
-
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza
NCT05227001 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
NCT04961541 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
NCT04969276 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
NCT05519839 ·Status: COMPLETED ·Phase: PHASE2
-
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
NCT06695117 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
NCT05333289 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
NCT00644059 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine
NCT03927131 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
NCT05827068 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
NCT05585632 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines
NCT00735020 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
NCT06508320 ·Status: COMPLETED ·Phase: PHASE2